

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 9, 2020

INTRICON CORPORATION

(Exact name of registrant as specified in its charter)

Pennsylvania

(State or other jurisdiction of incorporation)

1-5005

(Commission File Number)

23-1069060

(IRS Employer Identification No.)

1260 Red Fox Road, Arden Hills, MN 55112

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (651) 636-9770

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, par value \$1.00 per share	IIN	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

The following information is being provided pursuant to Item 2.02. Such information, including Exhibit 99.1 attached hereto, should not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

On November 9, 2020, IntriCon Corporation (the "Company") announced earnings for the quarter ended September 30, 2020. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

The following information is being provided pursuant to Item 7.01. Such information, including Exhibit 99.1 attached hereto, should not be deemed "filed" for purposes of Section 18 of the Exchange Act.

The information contained under Item 2.02 is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press Release Dated November 9, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTRICON CORPORATION

By: /s/ Scott Longval
Name: Scott Longval
Title: President, Chief Executive Officer and Chief Financial Officer

Date: November 9, 2020

Exhibit Index

Exhibit Number

Description

[99.1](#)

[Press Release Dated November 9, 2020](#)

INTRICON REPORTS THIRD QUARTER 2020 RESULTS

ARDEN HILLS, Minn. — November 9, 2020 — Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering and manufacturing miniature interventional, implantable and body-worn medical devices, today announced financial results for its third quarter ended September 30, 2020.

“Third quarter results included both year-over-year and sequential revenue growth as we see improvement across all our target medical markets. Continued emphasis on expense control while leveraging our core competencies to enter new medical markets for long-term growth remains a priority,” said Scott Longval, President and Chief Executive Officer. “Our acquisition of Emerald Medical Services earlier this year is already demonstrating a meaningful contribution, while our directed focus on partnerships with innovators entering the emerging hearing health market is gaining traction.”

Third Quarter Highlights:

- Revenue of \$27.4 million compared to \$26.9 million in the prior year
 - Diabetes revenue declined 7.7% year-over-year
 - Other medical revenue increased 81.6% year-over-year, which included the contribution from recently acquired Emerald Medical Services
- Gross margin of 26.3%, compared to 25.2% in the prior year period
- Net income per diluted share of \$0.07 versus net loss of \$0.03 per diluted share in the prior year period

Third Quarter 2020 Financial Results

For the 2020 third quarter, the company reported net revenue of \$27.4 million versus \$26.9 million in the comparable prior-year period.

Revenue in Intricon’s Medical business was \$20.6 million, an increase from \$19.1 million in the comparable prior-year period. The year-over-year increase was driven primarily by our medical coils business and the impact of Emerald Medical Services which the company acquired in May 2020, partially offset by the reduction in orders due to uncertainty surrounding the COVID-19 pandemic.

Hearing Health revenue was \$5.5 million in the third quarter of 2020 compared to \$6.4 million in the prior-year third quarter. The revenue decline during the third quarter was largely attributed to the absence of hi Health Innovations revenue and a reduction in advertising as part of the Hearing Help Express restructuring efforts.

Gross margin in the third quarter of 2020 was 26.3%, compared to 25.2% in the prior-year third quarter, primarily due to the cost reduction initiatives and higher volumes.

Operating expenses for the third quarter were \$6.7 million, compared to \$7.2 million in the comparable prior-year period. The change in operating expenses year over year was due to the cost reduction initiatives.

The company posted a net income of \$0.6 million or \$0.07 per diluted share in the third quarter of 2020, versus net loss of \$0.3 million or \$0.03 per diluted share, for the 2019 third quarter.

(more)

Conference Call

Intricon will hold a conference call today, November 9, 2020, beginning at 4:00 p.m. CT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 866-795-7248 for domestic callers or 470-495-9160 for international callers, using conference ID: 6348919. A live and archived webcast will be available on the “Investors” sections of the company’s website at: www.Intricon.com.

Forward-Looking Statements

Statements made in this release and in Intricon’s other public filings and releases that are not historical facts or that include forward-looking terminology, including estimates of future results, the impact of the Emerald acquisition, statements regarding the estimated costs and expenses of the restructuring and estimated annual expense savings, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be affected by known and unknown risks, uncertainties and other factors that are beyond Intricon’s control, including without limitation, the impacts of the COVID-19 pandemic and measures taken in response, the risks associated with the Emerald acquisition, , and may cause Intricon’s actual results, performance or achievements to differ materially from the results, performance and achievements expressed or implied in the forward-looking statements. These risks, uncertainties and other factors are detailed from time to time in the company’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2019 and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. The company disclaims any intent or obligation to publicly update or revise any forward-looking statements, regardless of whether new information becomes available, future developments occur or otherwise.

About Intricon Corporation

Headquartered in Arden Hills, Minn., Intricon Corporation designs, develops and manufactures miniature interventional, implantable and body-worn devices. These advanced products help medical, healthcare and professional communications companies meet the rising demand for smaller, more intelligent and better-connected devices. Intricon has facilities in the United States, Asia, and Europe. The company’s common stock trades under the symbol “IIN” on the NASDAQ Global Market. For more information about Intricon, visit www.intricon.com.

Investor Contact

Leigh Salvo
(415) 937-5404
investorrelations@intricon.com

TRICON CORPORATION
MARKET REVENUE
(Unaudited)

(\$ in 000's)	THIRD QUARTER			YEAR TO DATE		
	2020	2019	Change	2020	2019	Change
Medical	\$ 20,649	\$ 19,099	8.1%	\$ 55,125	\$ 60,784	-9.3%
Diabetes	14,518	15,723	-7.7%	41,569	50,837	-18.2%
Other Medical	6,131	3,376	81.6%	13,556	9,947	36.3%
Hearing Health	5,491	6,358	-13.6%	13,845	20,044	-30.9%
Value Based Direct-to-End-Consumer	953	1,510	-36.9%	3,513	4,876	-28.0%
Value Based Indirect-to-End-Consumer	1,779	2,443	-27.2%	3,888	7,419	-47.6%
Legacy OEM	2,759	2,405	14.7%	6,444	7,749	-16.8%
Professional Audio Communications	1,227	1,436	-14.6%	3,502	4,972	-29.6%
Total	<u>\$ 27,367</u>	<u>\$ 26,893</u>	1.8%	<u>\$ 72,472</u>	<u>\$ 85,800</u>	-15.5%

INTRICON CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Amounts)

(unaudited)	Three Months Ended		Nine Months Ended	
	September 30, 2020	September 30, 2019	September 30, 2020	September 30, 2019
Revenue, net	\$ 27,367	\$ 26,893	\$ 72,472	\$ 85,800
Cost of goods sold	20,169	20,120	54,096	62,253
Gross profit	7,198	6,773	18,376	23,547
Operating expenses:				
Sales and marketing	1,365	2,609	5,038	9,071
General and administrative	3,654	3,715	11,673	10,551
Research and development	1,458	840	3,868	2,902
Restructuring charges	—	—	1,171	—
Impairment loss	—	—	—	3,765
Other operating expenses	253	—	746	—
Total operating expenses	6,730	7,164	22,496	26,289
Operating income (loss)	468	(391)	(4,120)	(2,742)
Interest income, net	41	240	322	703
Other income (expense), net	192	(52)	293	(458)
Income (loss) from continuing operations before income taxes and discontinued operations	701	(203)	(3,505)	(2,497)
Income tax expense	47	87	94	334
Income (loss) from continuing operations before discontinued operations	654	(290)	(3,599)	(2,831)
Loss on disposal of discontinued operations	—	—	—	(1,116)
Loss from discontinued operations	—	—	—	(597)
Net income (loss)	654	(290)	(3,599)	(4,544)
Less: Income allocated to non-controlling interest	10	—	17	—
Net income (loss) attributable to IntriCon shareholders	\$ 644	\$ (290)	\$ (3,616)	\$ (4,544)
Basic income (loss) per share attributable to IntriCon shareholders:				
Continuing operations	\$ 0.07	\$ (0.03)	\$ (0.41)	\$ (0.32)
Discontinued operations	—	—	—	(0.20)
Net income (loss) per share:	\$ 0.07	\$ (0.03)	\$ (0.41)	\$ (0.52)
Diluted income (loss) per share attributable to IntriCon shareholders:				
Continuing operations	\$ 0.07	\$ (0.03)	\$ (0.41)	\$ (0.32)
Discontinued operations	—	—	—	(0.20)
Net income (loss) per share:	\$ 0.07	\$ (0.03)	\$ (0.41)	\$ (0.52)
Average shares outstanding:				
Basic	8,936	8,764	8,877	8,738
Diluted	9,272	8,764	8,877	8,738

INTRICON CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEET
(In Thousands, Except Share Amounts)

(unaudited)	September 30,	December 31,
	2020	2019
Current assets:		
Cash and cash equivalents	\$ 16,081	\$ 8,523
Restricted cash	647	639
Short-term investment securities	14,176	23,451
Accounts receivable, less provision for doubtful accounts of \$365 at September 30, 2020 and \$325 at December 31, 2019	9,192	8,993
Inventories	20,463	16,377
Contract assets	10,592	10,237
Other current assets	1,426	1,975
Current assets of discontinued operations	—	80
Total current assets	72,577	70,275
Machinery and equipment	45,083	41,073
Less: Accumulated depreciation	30,915	27,522
Net machinery and equipment	14,168	13,551
Goodwill	13,714	9,551
Intangible assets	11,282	5,545
Operating lease right-of-use assets, net	3,812	4,372
Investment in partnerships	623	1,160
Long-term investment securities	—	8,629
Other assets, net	289	510
Total assets	\$ 116,465	\$ 113,593
Current liabilities:		
Current financing leases	\$ 34	\$ 101
Current operating leases	1,512	1,729
Accounts payable	8,340	9,876
Accrued salaries, wages and commissions	4,271	2,274
Other accrued liabilities	4,429	2,869
Liabilities of discontinued operations	—	77
Total current liabilities	18,586	16,926
Noncurrent financing leases	2	30
Noncurrent operating leases	2,475	2,937
Other postretirement benefit obligations	349	382
Accrued pension liabilities	667	655
Deferred tax liabilities, net	1,104	—
Other long-term liabilities	3,790	2,171
Total liabilities	26,973	23,101
Commitments and contingencies		
Shareholders' equity:		
Common stock, \$1.00 par value per share; 20,000 shares authorized; 8,943 and 8,781 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	8,943	8,781
Additional paid-in capital	88,908	86,770
Accumulated deficit	(7,902)	(4,286)
Accumulated other comprehensive loss	(474)	(520)
Total shareholders' equity	89,475	90,745
Non-controlling interest	17	(253)
Total equity	89,492	90,492
Total liabilities and equity	\$ 116,465	\$ 113,593